Objective-To compare the efficacy and safety of azithromycin and doxycycline in the treatment of males with uncomplicated urethritis caused by chlamydia trachomatis. Design-A multicentre, double-blind, randomised treatment study.
Introduction
Chlamydia trachomatis (CT) causes substantial morbidity in young sexually active people. CT infection is the most frequent identifiable single cause of pelvic inflammatory disease (PID) and female infertility. The microorganism is a common cause of male urethritis. Complications from urethritis are now more common if the urethritis is due to chlamydia than if it is due to gonococci. Unlike patients with gonococcal urethritis, those with chlamydial urethritis tend to have less pronounced symptoms and signs, quite a few cases being completely asymptomatic. Patient noncompliance is a well known problem in the treatment of urogenital chlamydial infections with traditional 7-10 days courses of tetracyclines or erythromycin. This problem is particularly significant in patients with asymptomatic infection. Unlike gonococcal infections, there is currently no single-dose regimen available for the treatment of urogenital chlamydial infections.
Azithromycin has been shown to posess interesting pharmacokinetic properties. In contrast to low serum levels, high and sustained concentrations are found in a variety of different tissues including the urogenital tract.' Furthermore, azithromycin has been shown to be highly active in vitro against several sexually transmittable agents including CT.23 Especially because of the long tissue half life, this drug would seem to be an interesting candidate as a single-dose treatment regimen in chlamydial urethritis.
The objective of the present study was to compare the efficacy and safety of azithromycin and doxycycline in the treatment of males with uncomplicated urethritis caused by CT. Blood and urine specimen were also repeated after 4 weeks. The patients were advised to observe sexual abstinence throughout their participation in the study.
Patients and methods
In order of presentation patients who satisfied the entry criteria were assigned to oral regimens of either azithromycin or doxycycline according to a pre-determined randomisation list. Patients assigned to azithromycin were to take a single 1000 mg dose as four capsules on the morning of day 1. Additionally they were to Chlamydial culture Urethral samples were collected with a wiremounted cotton-tipped swab. After collection the swabs were transported to the laboratory in In our study both treatment groups reported a rather high incidence of side effects (table 4) ; the difference between the two treatment groups was not statistically significant. As in other studies6`8 mild to moderate gastrointestinal side effects dominated. We believe that the study design itself may be partly responsible for the unexpected high incidence of reported side effects, as all patients were asked specifically at every visit if they had noticed anything that might be a drug related side effect. In this context, it is worth noticing that no patient wanted to withdraw from the study because of side effects. Furthermore, it is known that adverse effects generally tend to be more frequent when treating sexually transmitted diseases and urinary tract infections as compared with other infections.'0 Additionally, the incidence of adverse effects also tends to be significantly higher in blinded than in open studies.`0 So far, the results from this double-blind study demonstrate that azithromycin administered as a single 1000 mg dose to male patients with urethritis caused by CT is as effective and safe as a standard course of doxycycline. Azithromycin might turn out to be the drug of choice in genital chlamydial infections.
